N19 Polyepitope As a Carrier for Enhanced Immunogenicity and Protective Efficacy of Meningococcal Conjugate Vaccines

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2004 Jul 24

PMID 15271954

Citations 13

Authors

Karin Baraldo

Elena Mori

Antonella Bartoloni

Roberto Petracca

Aldo Giannozzi

Francesco Norelli

Rino Rappuoli

Guido Grandi

Giuseppe Del Giudice

Affiliations

Soon will be listed here.

Abstract

N19, a string of human universal CD4 T-cell epitopes from various pathogen-derived antigens, was shown to exert a stronger carrier effect than CRM197 for the induction of anti-group C Neisseria meningitidis capsular polysaccharide (MenC), after immunization of mice with various dosages of N19-MenC or CRM-MenC conjugate vaccines. After two immunizations, the N19-based construct induced anti-MenC antibody and protective bactericidal antibody titers higher than those induced by three doses of the CRM-MenC conjugate and required lower amounts of conjugate. N19-based conjugates are superior to CRM-based conjugates to induce protective immune responses to MenC conjugates.

Citing Articles

Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines.

Micoli F, Stefanetti G, MacLennan C Front Mol Biosci. 2023; 10:1201693.

PMID: 37261327 PMC: 10227950. DOI: 10.3389/fmolb.2023.1201693.

Rotavirus spike protein ΔVP8* as a novel carrier protein for conjugate vaccine platform with demonstrated antigenic potential for use as bivalent vaccine.

Park W, Yoon Y, Park J, Pansuriya R, Seok Y, Ganapathy R Sci Rep. 2021; 11(1):22037.

PMID: 34764353 PMC: 8586335. DOI: 10.1038/s41598-021-01549-z.

Enhanced Immunogenicity and Protective Efficacy of a Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21.

Ramakrishnan A, Schumack N, Gariepy C, Eggleston H, Nunez G, Espinoza N mSphere. 2019; 4(3).

PMID: 31043512 PMC: 6495334. DOI: 10.1128/mSphere.00101-19.

Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni and Shigella.

Laird R, Ma Z, Dorabawila N, Pequegnat B, Omari E, Liu Y Vaccine. 2018; 36(45):6695-6702.

PMID: 30269917 PMC: 6223012. DOI: 10.1016/j.vaccine.2018.09.052.

Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends.

Micoli F, Adamo R, Costantino P Molecules. 2018; 23(6).

PMID: 29914046 PMC: 6100388. DOI: 10.3390/molecules23061451.

References

McVernon J, Maclennan J, Clutterbuck E, Buttery J, Moxon E . Effect of infant immunisation with meningococcus serogroup C-CRM(197) conjugate vaccine on diphtheria immunity and reactogenicity in pre-school aged children. Vaccine. 2003; 21(19-20):2573-9. DOI: 10.1016/s0264-410x(03)00058-6. View

Balmer P, Borrow R, Miller E . Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002; 51(9):717-722. DOI: 10.1099/0022-1317-51-9-717. View

Etlinger H, Gillessen D, Lahm H, Matile H, Schonfeld H, Trzeciak A . Use of prior vaccinations for the development of new vaccines. Science. 1990; 249(4967):423-5. DOI: 10.1126/science.1696030. View

Carlone G, Frasch C, Siber G, Quataert S, Gheesling L, Turner S . Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J Clin Microbiol. 1992; 30(1):154-9. PMC: 265012. DOI: 10.1128/jcm.30.1.154-159.1992. View

Barrios C, Lussow A, van Embden J, van der Zee R, Rappuoli R, Costantino P . Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guérin priming. Eur J Immunol. 1992; 22(6):1365-72. DOI: 10.1002/eji.1830220606. View

Valmori D, Pessi A, Bianchi E, Corradin G . Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J Immunol. 1992; 149(2):717-21. View

Del Giudice G . New carriers and adjuvants in the development of vaccines. Curr Opin Immunol. 1992; 4(4):454-9. DOI: 10.1016/s0952-7915(06)80038-5. View

Maslanka S, Gheesling L, Libutti D, Donaldson K, Harakeh H, Dykes J . Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997; 4(2):156-67. PMC: 170495. DOI: 10.1128/cdli.4.2.156-167.1997. View

Granoff D, Maslanka S, Carlone G, Plikaytis B, Santos G, Mokatrin A . A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol. 1998; 5(4):479-85. PMC: 95603. DOI: 10.1128/CDLI.5.4.479-485.1998. View

10.

Fattom A, Cho Y, Chu C, Fuller S, Fries L, Naso R . Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine. 1999; 17(2):126-33. DOI: 10.1016/s0264-410x(98)00162-5. View

11.

Costantino P, Norelli F, Giannozzi A, DAscenzi S, Bartoloni A, Kaur S . Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines. Vaccine. 1999; 17(9-10):1251-63. DOI: 10.1016/s0264-410x(98)00348-x. View

12.

Keitel W, Kester K, Atmar R, White A, Bond N, Holland C . Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine. 1999; 18(5-6):531-9. DOI: 10.1016/s0264-410x(99)00221-2. View

13.

Svennerholm L . Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta. 1957; 24(3):604-11. DOI: 10.1016/0006-3002(57)90254-8. View

14.

Alexander J, del Guercio M, Maewal A, Qiao L, Fikes J, Chesnut R . Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol. 2000; 164(3):1625-33. DOI: 10.4049/jimmunol.164.3.1625. View

15.

Diethelm-Okita B, Okita D, Banaszak L, Conti-Fine B . Universal epitopes for human CD4+ cells on tetanus and diphtheria toxins. J Infect Dis. 2000; 181(3):1001-9. DOI: 10.1086/315324. View

16.

Peltola H . Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2001; 13(2):302-17. PMC: 100154. DOI: 10.1128/CMR.13.2.302. View

17.

Falugi F, Petracca R, Mariani M, Luzzi E, Mancianti S, Carinci V . Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines. Eur J Immunol. 2001; 31(12):3816-24. DOI: 10.1002/1521-4141(200112)31:12<3816::AID-IMMU3816>3.0.CO;2-K. View

18.

Wuorimaa T, Kayhty H . Current state of pneumococcal vaccines. Scand J Immunol. 2002; 56(2):111-29. DOI: 10.1046/j.1365-3083.2002.01124.x. View

19.

Balmer P, Borrow R . Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev Vaccines. 2004; 3(1):77-87. DOI: 10.1586/14760584.3.1.77. View